Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.

Join us as we explored:

Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment.

Listen us on:

Follow us on social media:

•⁠  ⁠X/Twitter: https://x.com/oncbrothers 

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! 

#Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).

We dived deep into the side effect profiles and management strategies for key treatments, including:

Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

Subscribe for more insights and updates from the Oncology Brothers!

#PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications.

Key topics discussed included:

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes!

#Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).

Join us as we delved into:

Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care!

#PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari, a myeloma specialist, nurse practitioner Samantha Shenoy, NP, and clinical nurse Jenny Truong, RN.

In this insightful discussion, we covered:

Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer care, this episode offers valuable insights into the complexities of treating multiple myeloma.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!

#MultipleMyeloma, #QuadTherapy, #Daratumumab, #Isatuximab, #OncologyBrothers

We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody.

We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab.

Key topics covered in this episode:

Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies.

Follow us on social media:

Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases!

#GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers

Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.

The panel covers:

This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers!

#MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma.

Join us as we dive into:

This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in multiple myeloma treatment.

Listen us on:

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#CELMoDs, #MultipleMyeloma, #EXCALIBERstudy, #MRD, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more.

Key topics included:

Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care.

Listen us on:

Follow us on social media:

Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers!

#ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers

Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression.

In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept, and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification and the potential for improved patient outcomes.

The second case featured a 67-year-old woman whose disease has progressed despite initial treatment with luspatercept. Dr. Zeidan shared insights on the next steps, including the use of hypomethylating agents (HMAs) , the role of transplant, and the management of side effects associated with these therapies.

Tune in for an informative discussion that not only addressed treatment strategies but also emphasized the importance of patient-centered care and the need for ongoing monitoring and support.

Don't forget to like, subscribe, and share your thoughts with us! If there are specific topics or cases you'd like us to cover in future episodes, reach out to us.

Episode Highlights:

Listen us on:

Follow us on social media:

Thanks for tuning in! We are the Oncology Brothers.

#MDS, #MyelodysplasticSyndrome, #HMAs, #HemeMalignancy, #OncologyBrothers